(Axios) – Big drug companies have been buying scrappy biotechs to expand their pipelines, but the potential megamerger between AstraZeneca and Bristol Myers Squibb could flip that script.

Why it matters: Combining two drug giants with overlapping portfolios could put cost efficiencies ahead of innovation. (Read More)